Andere talen Merck & Co., Inc.

Aandelen

MRK

US58933Y1055

Farmaceutische producten

Beurs gesloten - NYSE Andere beurzen 22:03:18 11-06-2026			Nabeurs 01:55:06
120,76 ^USD	+1,40%		121,31	+0,46%

11/06	Ontwikkelaars van afslankmedicijnen staan in de rij voor lucratieve markt terwijl concurrentie toeneemt	RE
11/06	Merck neemt Targan over om technologische positie in diergezondheid te versterken	MT

Andere talen

11/06	Weight-loss drug developers line up to tap lucrative market as competition heats up
11/06	Merck Bolsters Animal-Health Unit With Deal to Buy Targan
11/06	Merck to Acquire Poultry Biodevice Firm Targan to Expand Animal Health Tech
11/06	Merck to Acquire Poultry Biodevice Firm Targan to Expand Animal Health Tech
11/06	Merck Animal Health to Acquire TARGAN
11/06	BioInvent’s TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA® (pembrolizumab) in Advanced CTCL (EHA 2026)
09/06	What Bundibugyo Ebola vaccines and treatments are under development
09/06	Weight-loss drug developers line up to tap lucrative market as competition heats up
09/06	Cancer vaccines based on mRNA advance, despite US cuts
09/06	Bourse : GSK s'offre Nuvalent pour 10,6 MdsUSD, RIP le SCAF, Orange seul maître à bord en Espagne
09/06	La tech se remet la tête à l'endroit
08/06	Gilead, Merck HIV Combination Meets Primary Endpoint in Two Phase 3 Trials
08/06	Merck, Gilead End Lung Cancer Trial, Report Positive Data From HIV Drug Trials
08/06	Merck, Gilead Discontinue Phase 3 Trial of Trodelvy, Keytruda to Treat Lung Cancer
08/06	Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
08/06	Gilead Sciences, Inc. And Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, An Oral Once-Weekly HIV Treatment
08/06	Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
08/06	Merck and Gilead Sciences, Inc. Provides Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
04/06	Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases
04/06	Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases, Bloomberg Reports
04/06	MÄRKTE USA/Uneinheitlich - Gewinnmitnahmen im Technologiesektor
04/06	What Bundibugyo Ebola vaccines and treatments are under development
04/06	MÄRKTE USA/Uneinheitlich - Gewinnmitnahmen im Technologiesektor
03/06	HEALTH ROUNDS-Radiation-emitting implant improves outcomes after brain cancer surgery
03/06	Avis d'analystes du jour : Richemont, ST et Publicis entourées